DRG Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL …
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the…
Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL)…
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia…
Antibody drug conjugates (ADCs) are a class of drug therapies that combine the targeting abilities of monoclonal antibodies with the cancer-killing activities of cytotoxic agents. ADCs can…
The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig…